CO2020013252A2 - Dosificación subcutánea de anticuerpos anti-cd38 - Google Patents

Dosificación subcutánea de anticuerpos anti-cd38

Info

Publication number
CO2020013252A2
CO2020013252A2 CONC2020/0013252A CO2020013252A CO2020013252A2 CO 2020013252 A2 CO2020013252 A2 CO 2020013252A2 CO 2020013252 A CO2020013252 A CO 2020013252A CO 2020013252 A2 CO2020013252 A2 CO 2020013252A2
Authority
CO
Colombia
Prior art keywords
antibodies
subcutaneous dosage
methods
cancers
subcutaneous
Prior art date
Application number
CONC2020/0013252A
Other languages
English (en)
Inventor
Eric Fedyk
Michael Hanley
Antonio Palumbo
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CO2020013252A2 publication Critical patent/CO2020013252A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen métodos para administrar anticuerpos anti-CD38 aislados por vía subcutánea. Los métodos proporcionan un tratamiento eficaz para las enfermedades autoinmunes y los cánceres, incluidas las enfermedades hematológicas. También se describen formas de dosificación unitaria para los anticuerpos anti-CD38.
CONC2020/0013252A 2018-03-28 2020-10-22 Dosificación subcutánea de anticuerpos anti-cd38 CO2020013252A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862649489P 2018-03-28 2018-03-28
PCT/IB2019/000314 WO2019186273A1 (en) 2018-03-28 2019-03-27 Subcutaneous dosing of anti-cd38 antibodies

Publications (1)

Publication Number Publication Date
CO2020013252A2 true CO2020013252A2 (es) 2020-11-10

Family

ID=66647425

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0013252A CO2020013252A2 (es) 2018-03-28 2020-10-22 Dosificación subcutánea de anticuerpos anti-cd38

Country Status (12)

Country Link
US (1) US20210047427A1 (es)
EP (1) EP3774915A1 (es)
JP (2) JP2021519295A (es)
KR (1) KR20210002499A (es)
CN (1) CN112154156A (es)
AU (1) AU2019244478A1 (es)
BR (1) BR112020019710A2 (es)
CA (1) CA3095086A1 (es)
CO (1) CO2020013252A2 (es)
MX (1) MX2020010144A (es)
TW (1) TW202003566A (es)
WO (1) WO2019186273A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
EP3227338A4 (en) 2014-12-04 2018-05-16 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of acute myeloid leukemia
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
MA53356B1 (fr) 2015-11-03 2022-05-31 Janssen Biotech Inc Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
CA3079242A1 (en) 2017-10-31 2019-05-09 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
CA3111651A1 (en) * 2018-09-11 2020-03-19 Jiangsu Hengrui Medicine Co., Ltd. Anti-cd38 antibody, antigen-binding fragment thereof, and pharmaceutical use
JP2022512722A (ja) * 2018-10-17 2022-02-07 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体の皮下投与を提供する方法
CN115884767A (zh) * 2020-05-15 2023-03-31 武田药品工业株式会社 Sumo活化酶抑制剂和抗cd38抗体的施用
IL310372A (en) 2021-07-28 2024-03-01 Genentech Inc IL15/IL15R alpha heterodimeric FC-fused proteins for the treatment of blood cancer
AU2022350815A1 (en) * 2021-09-23 2024-05-02 Sound Biopharmaceuticals Co. Ltd. Cd38 monoclonal antibody and application thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
IT1320715B1 (it) 2000-10-19 2003-12-10 Cselt Centro Studi Lab Telecom Modulo generatore di circuiti per la decodifica di codiciconvoluzionali, metodo per la generazione di tale tipo di circuito e
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
EP1411851B1 (en) 2001-08-03 2006-11-02 Tyco Healthcare Group LP Marker for use with a tissue marking apparatus
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
WO2006125640A2 (en) 2005-05-24 2006-11-30 Morphosys Ag Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38
SI2567976T1 (sl) * 2005-03-23 2017-11-30 Genmab A/S Protitelesa usmerjena proti cd38 za zdravljenje multiplega mieloma
EP1931709B1 (en) 2005-10-03 2016-12-07 Xencor, Inc. Fc variants with optimized fc receptor binding properties
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
TN2016000142A1 (en) * 2013-10-31 2017-10-06 Sanofi Sa Specific anti-cd38 antibodies for treating human cancers.
US10533057B2 (en) * 2015-05-13 2020-01-14 Morphosys Ag Treatment for multiple myeloma (MM)
MA53356B1 (fr) * 2015-11-03 2022-05-31 Janssen Biotech Inc Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
WO2018013917A1 (en) * 2016-07-15 2018-01-18 Takeda Pharmaceutical Company Limited Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies

Also Published As

Publication number Publication date
JP2024045121A (ja) 2024-04-02
KR20210002499A (ko) 2021-01-08
AU2019244478A1 (en) 2020-11-12
RU2020135062A (ru) 2022-04-28
MX2020010144A (es) 2020-12-07
WO2019186273A1 (en) 2019-10-03
CA3095086A1 (en) 2019-10-03
EP3774915A1 (en) 2021-02-17
TW202003566A (zh) 2020-01-16
BR112020019710A2 (pt) 2021-01-26
JP2021519295A (ja) 2021-08-10
CN112154156A (zh) 2020-12-29
RU2020135062A3 (es) 2022-04-28
WO2019186273A4 (en) 2019-12-19
US20210047427A1 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
CO2020013252A2 (es) Dosificación subcutánea de anticuerpos anti-cd38
MX2020010458A (es) Conjugados de camptotecina-peptido.
EA202091134A1 (ru) Экзосомы для иммуноонкологической и противовоспалительной терапии
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
UY38236A (es) COMBINACIONES FARMACÉUTICAS QUE CONTIENEN EL ANTICUERPO ANTI-CD38, ASOCIADO CON LOS ANTICUERPOS BIOESPECÍFICOS BCMAxCD3 O GPRC5DxCD3 O CD19xCD3
CR20190376A (es) Formulaciones de anticuerpos de her2 subcutáneas
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
CO2017004516A2 (es) Anticuerpos anti-ox40 humanizados
EA201892294A1 (ru) Антитела и композиции против tim-3
PH12020552229A1 (en) Il-11ra antibodies
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
EA201890530A1 (ru) Конъюгаты антитела к dll3 и лекарственного средства и способы их применения
EA201791736A1 (ru) Комбинированная терапия для лечения рака
EA201891399A1 (ru) Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний
MX2022003930A (es) Conjugados de péptido de camptotecina.
EA201892284A1 (ru) Комбинация антитела против cd20, селективного ингибитора pi3-киназы-дельта и ингибитора btk для лечения b-клеточных пролиферативных расстройств
EA202092302A1 (ru) Антитела к trem-1 и их применения
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
CL2021001593A1 (es) Tubulisinas y conjugados de proteína-tubulisina
EA201990370A1 (ru) Терапия рака, связанная с crebbp
CO2020008561A2 (es) Dosificación subcutánea de anticuerpos anti-cd38
EA202190862A1 (ru) Способы лечения
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
EA201791819A1 (ru) Комбинированная терапия с применением конъюгата антитела против cd19 с лекарственным средством и винкристина